Shen Yu, Qu Qiu-Xia, Zhu Yi-Bei, Zhang Xue-Guang
Clinical Immunology Institute of Jiangsu Province, The First Affiliated Hospital of Soochow University, Suzhou, China.
J Immunoassay Immunochem. 2012;33(2):149-55. doi: 10.1080/15321819.2011.609575.
Host anti-tumor immune responses can be attenuated by suppressor T cells of the phenotype CD8(+)CD28(-) (T(s) cells). In the present study, we investigated the presence of CD8(+)CD28(-) (T(s) cells) in the peripheral blood compartment of gastric cancer (GC) patients. Flow cytometry was used to detect the population of CD8(+)CD28(-) T(s) cells present in peripheral blood in therapy naïve patients with gastric cancer (n = 26), postoperative chemotherapy naïve gastric cancer patients (n = 23), and healthy controls (n = 27). Meanwhile, the clinical data of gastric cancer patients were analyzed. A significant difference in the percentage of T(s) cells was observed when comparing peripheral blood samples from cancer patients to healthy volunteers (27.08 ± 1.60% versus 10.86 ± 0.75%). In the patient group, the percentage of CD8(+)CD28(-) cells among lymphocytes was higher in patients with LN metastasis than those without LN metastasis. The percentage of CD8(+)CD28(-) cells was also related to tumor infiltration and size, but not with the degree of differentiation of cancer cells. Moreover, the percentage of CD8(+)CD28(-) cells was higher in preoperative gastric cancer patients (26.24 ± 1.78%) than in those of postoperation patients (15.79 ± 1.11%). These findings may reflect the possibility of tumor-induced immunosuppression, and they should be complemented with further studies.
宿主抗肿瘤免疫反应可被表型为CD8(+)CD28(-)的抑制性T细胞（T(s)细胞）减弱。在本研究中，我们调查了胃癌（GC）患者外周血中CD8(+)CD28(-)（T(s)细胞）的存在情况。采用流式细胞术检测初治胃癌患者（n = 26）、术后未接受化疗的胃癌患者（n = 23）和健康对照者（n = 27）外周血中CD8(+)CD28(-) T(s)细胞的数量。同时，分析了胃癌患者的临床资料。将癌症患者的外周血样本与健康志愿者的样本进行比较时，观察到T(s)细胞百分比存在显著差异（27.08 ± 1.60%对10.86 ± 0.75%）。在患者组中，有淋巴结转移的患者淋巴细胞中CD8(+)CD28(-)细胞的百分比高于无淋巴结转移的患者。CD8(+)CD28(-)细胞的百分比也与肿瘤浸润和大小有关，但与癌细胞的分化程度无关。此外，术前胃癌患者CD8(+)CD28(-)细胞的百分比（26.24 ± 1.78%）高于术后患者（15.79 ± 1.11%）。这些发现可能反映了肿瘤诱导免疫抑制的可能性，应通过进一步研究加以补充。
